Tallac Therapeutics™ is a privately held clinical stage biopharmaceutical company based in the San Francisco Bay Area. Our multi-disciplinary team is rapidly advancing company’s lead oncology programs in multiple indications. Tallac’s pipeline of oligonucleotide-based ADC candidates includes novel Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to systemically deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) and trigger immune activation within the tumor microenvironment. Several TRAAC molecules are in various stages of discovery and development, including two programs in the clinic.